Related references
Note: Only part of the references are listed.Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
Gerd R. Burmester et al.
LANCET (2013)
Serum interleukin-6 levels in response to methotrexate treatment in psoriatic patients
Tamilselvi Elango et al.
CLINICA CHIMICA ACTA (2012)
Tetracyclines Convert the Osteoclastic-Differentiation Pathway of Progenitor Cells To Produce Dendritic Cell-like Cells
Saya Kinugawa et al.
JOURNAL OF IMMUNOLOGY (2012)
The osteoclast and its unique cytoskeleton
Steven L. Teitelbaum
SKELETAL BIOLOGY AND MEDICINE II: BONE AND CARTILAGE HOMEOSTASIS AND BONE DISEASE (2011)
IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis
Tomoaki Mori et al.
INTERNATIONAL IMMUNOLOGY (2011)
Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial
Jacques P. Brown et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Dissecting Specificity in the Janus Kinases: The Structures of JAK-Specific Inhibitors Complexed to the JAK1 and JAK2 Protein Tyrosine Kinase Domains
Neal K. Williams et al.
JOURNAL OF MOLECULAR BIOLOGY (2009)
Interleukin-6 inhibits receptor activator of nuclear factor κB ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage:: Key role of Serine727 phosphorylation of signal transducer and activator of transcription 3
Laurence Duplomb et al.
ENDOCRINOLOGY (2008)
Pathological role of osteoclast costimulation in arthritis-induced bone loss
Sae Ochi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Regulation of osteoclast differentiation and function by the CaMK-CREB pathway
Kojiro Sato et al.
NATURE MEDICINE (2006)
Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction
Kojiro Sato et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Interleukin 6: from bench to bedside
Norihiro Nishimoto et al.
NATURE CLINICAL PRACTICE RHEUMATOLOGY (2006)
Spatiotemporal regulation of c-Fos by ERK5 and the E3 ubiquitin ligase UBR1, and its biological role
Takanori Sasaki et al.
MOLECULAR CELL (2006)
Osteoclasts; culprits in inflammatory osteolysis
SL Teitelbaum
ARTHRITIS RESEARCH & THERAPY (2006)
M-CSF mediates TNF-induced inflammatory osteolysis
H Kitaura et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis
N Kim et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
IL-1 mediates TNF-induced osteoclastogenesis
S Wei et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Cytoplasmic c-Fos induced by the YXXQ-derived STAT3 signal requires the co-operative MEK/ERK signal for its nuclear translocation
N Higashi et al.
GENES TO CELLS (2004)
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
L Klareskog et al.
LANCET (2004)
Marrow stromal cells and osteoclast precursors differentially contribute to TNF-α-induced osteoclastogenesis in vivo
H Kitaura et al.
JOURNAL OF IMMUNOLOGY (2004)
Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis
A Sabokbar et al.
JOURNAL OF ORTHOPAEDIC RESEARCH (2003)
Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts
H Takayanagi et al.
DEVELOPMENTAL CELL (2002)
TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand
J Lam et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction
K Kobayashi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)